美國(guó)藥典最新版本（應(yīng)該是USP43) 胞磷膽堿鈉（Citicoline Sodium）質(zhì)量標(biāo)準(zhǔn) 需要紙質(zhì)掃描版，帶有USP43和頁(yè)碼 注：該標(biāo)準(zhǔn)上不能帶有其他印刷的文字   [更多]

求購(gòu)羥丙甲纖維素空心膠囊、普魯蘭多糖空心膠囊、明膠空心膠囊EP和USP最新版質(zhì)量標(biāo)準(zhǔn)！   [更多]

求查詢(xún)文獻(xiàn) SM-3997 drugs of future 1986,11,949（代）   [更多]

文獻(xiàn)均來(lái)自德國(guó)期刊，Arzneimittelforschung。要求是完整的文獻(xiàn)，必須完成第1篇。另請(qǐng)注意，英文標(biāo)題是翻譯過(guò)來(lái)的，原文標(biāo)題是德語(yǔ)。 1 [Ambroxol, comparative studies of pharmacokinetics and biotransformation in rat, rabbit, dog and man (author's transl)]. Hammer R, Bozler G, Jauch R, Koss FW, Hadamovsky H.Arzneimittelforschung. 1978;28(5a):899-903. 2 [Results of some clinical-pharmacological studies on ambroxol (NA 872)]. Renovanz VK.Arzneimittelforschung. 1975 Apr;25(4):646-52.PMID: 1174081 German. 3 Results from experimental studies in animals with the metabolite VIII of bromhexine (N-[trans-4-hydroxy-cyclohexyl]=[2-amino-3,5-dibromo-benzyl]-amine, Ambroxol (NA 842)) are described in order to contribute to the understanding of this substance's mode of action. ... 4 [Ambroxol, studies of biotransformation in man and determination in biological samples (author's transl)]. Jauch R, Bozler G, Hammer R, Koss FW, Karlsson M, Vitek E, H?ring I, Beschke K, Hadamovsky S, Maass D, Wollmann R.Arzneimittelforschung. 1978;28(5a):904-11. 5 [Pharmacological study on the bromhexine metabolite ambroxol (author's transl)]. Püschmann S, Engelhorn R.Arzneimittelforschung. 1978;28(5a):889-98.   [更多]

求購(gòu)日文文獻(xiàn)數(shù)篇 １ Ambroxol(NA872)の薬理作用についての研究 長(zhǎng)岡滋, 加瀬佳年* 薬理と治療 9(5): 1845-1854 1981 ２ アルタット(R)カプセル75の高血圧癥または高脂血癥を合併している高齢者における安全性について 醫(yī)學(xué)と薬學(xué) 54(6): 805-812 2005 ３ 消化性潰瘍に対するTZU-0460の臨床的検討 -主として安全性, 血液凝固系に及ぼす影響について- 臨牀と研究 62(9): 3037-3046 1985 ４ ヒスタミンH2受容體拮抗剤TZU-0460の胃酸分泌抑制作用 インシュリン刺激分泌抑制作用の検討 薬理と治療 13(3): 1471-1483 1985 ５ 塩酸ロキサチジンアセタート(TZU-0460)注射剤の第I相試験 臨床醫(yī)薬 5(12): 2485-2512 1989 ６ ヒスタミンH2受容體拮抗剤TZU-0460の胃酸分泌抑制作用 基礎(chǔ)分泌抑制作用の検討 薬理と治療 13(3): 1445-1453 1985   [更多]

DrugsoftheFuture（DOF）2020年8-10期 文獻(xiàn)必須完整、準(zhǔn)確   [更多]

求助：尼可地爾片注冊(cè)標(biāo)準(zhǔn)（最新的標(biāo)準(zhǔn)，不是JX20150161）！ 價(jià)格可以談！??！   [更多]

求購(gòu)HypromelloseCapsules《JP17(英)》的藥典標(biāo)準(zhǔn)一份   [更多]

https://journal.pda.org/content/41/3/88.short 要求完整的版本。   [更多]

1.Title：Studies of the polymorphism of sodium valproate. (Ger.). Authors：Kleinebudde P; Thies R Publication Name：Sci.Pharm. Publication Year：1999 Keywords：Valproate Sodium/Oc Crystal/Ft Polymorphism/Ft Calorimetry/Ft X-Ray- Diffraction/Ft Analysis/Ft Crystallography/Ft Anticonvulsants/Ft Antimanics / Ft Oc / Ft Extract：2 Crystal modifications (M1 and M2) of Na valproate (NV) have been detected at RT, while a further form (M3) occurred at temperatures above 100 deg. Untreated NV, which had been recrystallized from toluene or ethyl acetate occurred as modification M1. These modifications were examined by thermoanalytical (DSC, thermogravimetry) and X-ray crystallographic methods. 2.【題名】Polymorphism of sodium valproate 【作 者】Mifsud, H.;Miguel, L.;Lavastre, V.;Maire, G. 【刊 名】Calorim. Anal. Therm. Calorimetrie et Analyse Thermique 【出版日期】1993 【卷 號(hào)】Vol.24 【頁(yè) 碼】309-312 【關(guān)鍵詞】polymorphism sodium valproate Polymorphism of sodium valproate 1069-66-5 polymorphism 【摘 要】Polymorphism anal. is of fundamental pharmaceutical importance for correct development of a drug, as it provides valuable knowledge of its biopharmaceutical and technol. aspects. Indeed, different polymorphs exhibit different phys. properties that can affect bioavailability. Polymorphism screening has been developed in the authors' lab., based on crystn. parameter variations for a given drug in soln. Sodium valproate is an anti-epileptic drug commercialized under the name Depakine. Five polymorphic forms were obtained by the screening and characterized by differential scanning calorimetry, X-ray powder diffractometry, thermogravimetry and IR spectroscopy. The relationships between these forms were examd.   [更多]